ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat on Tuesday, November 12, 2024 at 2:30 ...

ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in the Virtual Investor Closing Bell Series on Thursday, ...

Group 1 - Outlook Therapeutics, Inc. has received regulatory approval in the European Union and the United Kingdom for the first authorized ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) [1][4] - The company participated in the 2nd Annual Chardan Virtual Ophthalmology Conference, focusing on age-related macular degeneration and diabetes-related ocular diseases, alongside seven other companies [2] - The commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK is expected in the first half of calendar 2025 [4] Group 2 - ONS-5010/LYTENAVA™ is currently investigational in the United States and is undergoing a non-inferiority study for wet AMD treatment [4] - If the ongoing study is successful, the data may support a resubmission of a Biologics License Application (BLA) to the FDA [4] - If approved in the United States, ONS-5010/LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4]

Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the completion of enrollment for its NORSE EIGHT clinical trial evaluating ONS-501 ...

Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD NORSE EIGHT current enrollment pace supports topline readout target of Q4 CY2024 Resubmission of the ONS-5010 Biologics License Application (BLA) on track for Q1 CY2025 Quarterly update conference call and webcast today, Wednesday, August 14th at 8:30 AM ET ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical com ...

ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference being held on Thursday, August 15, 2024. A video webcast of the fir ...

Core Viewpoint - Outlook Therapeutics has received regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab for treating wet AMD, with financial results for Q3 FY 2024 to be reported on August 14, 2024 [1][3]. Company Overview - Outlook Therapeutics is focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for retinal diseases, including wet AMD [3]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and the UK for wet AMD treatment [3]. - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and UK in Q1 2025 [3]. - In the US, ONS-5010/LYTENAVA™ is currently investigational and undergoing a non-inferiority study for wet AMD treatment, with potential plans to resubmit a BLA application to the FDA if successful [3]. Financial Reporting - The company will host a quarterly conference call and live audio webcast on August 14, 2024, at 8:30 AM ET to discuss operational and financial results [1][2].

Core Viewpoint - Outlook Therapeutics has received regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab for treating wet AMD, with financial results for Q3 FY 2024 to be reported on August 14, 2024 [1][3]. Company Overview - Outlook Therapeutics is focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for retinal diseases, including wet AMD [3]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and the UK for wet AMD treatment [3]. - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and UK in Q1 2025 [3]. - In the US, ONS-5010/LYTENAVA™ is currently investigational and undergoing a non-inferiority study for wet AMD treatment, with potential plans to resubmit a BLA application to the FDA if successful [3]. Financial Reporting - The company will host a quarterly conference call and live audio webcast on August 14, 2024, at 8:30 AM ET to discuss operational and financial results [1][2].

Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics will participate in a fireside chat at the BTIG Virtual Biotechnology Con ...

Outlook Therapeutics Today Outlook Therapeutics NASDAQ: OTLK has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target. Outlook Therapeutics -0.49 (-6.48%) ▼ Price Target $46.43 It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical factors such as float size and short interest. While the bullish price target is noteworthy, it's crucial to delve deeper into the company's fu ...